Connection
Bradley Martin to Cost-Benefit Analysis
This is a "connection" page, showing publications Bradley Martin has written about Cost-Benefit Analysis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.876 |
|
|
|
-
Shah A, Shewale A, Hayes CJ, Martin BC. Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients. Stroke. 2016 06; 47(6):1555-61.
Score: 0.490
-
Acharya M, Chopra D, Hayes CJ, Teeter B, Martin BC. Cost-Effectiveness of Intranasal Naloxone Distribution to High-Risk Prescription Opioid Users. Value Health. 2020 04; 23(4):451-460.
Score: 0.159
-
Hammond DA, Kathe N, Shah A, Martin BC. Cost-Effectiveness of Histamine2 Receptor Antagonists Versus Proton Pump Inhibitors for Stress Ulcer Prophylaxis in Critically Ill Patients. Pharmacotherapy. 2017 01; 37(1):43-53.
Score: 0.128
-
Ganguly R, Miller LS, Martin BC. Future employability, a new approach to cost-effectiveness analysis of antipsychotic therapy. Schizophr Res. 2003 Sep 01; 63(1-2):111-9.
Score: 0.051
-
Nerurkar J, Wade WE, Martin BC. Cost/death averted with venous thromboembolism prophylaxis in patients undergoing total knee replacement or knee arthroplasty. Pharmacotherapy. 2002 Aug; 22(8):990-1000.
Score: 0.047